Comparative proteomics among cytochrome p450 family 1 for differential substrate specificity

Siddharth S Kesharwani1, Prajwal P Nandekar, Preeti Pragyan

  • 1Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab, 160062, India.

The Protein Journal
|October 22, 2014
PubMed

Insights

Investigating Cytochrome P450 (CYP) isoforms like CYP1A1, CYP1A2, and CYP1B1 reveals key differences in their structures. These findings aid in designing targeted anticancer drugs that leverage CYP1A1

Area of Science:

  • Biochemistry
  • Structural Biology
  • Pharmacology

Background:

  • Cytochrome P450 enzymes (CYPs) are crucial in drug metabolism and interactions.
  • Overexpression of Cytochrome P450 1A1 (CYP1A1) in tumors presents a novel anticancer therapy strategy.
  • Understanding CYP substrate specificity is vital for drug design.

Purpose of the Study:

  • To comparatively analyze the protein structures of CYP1A1, CYP1A2, and CYP1B1.
  • To identify structural features governing substrate specificity among CYP1 family isoforms.
  • To inform the rational design of novel anticancer drugs targeting CYP1A1.

Main Methods:

  • Comparative protein structure analysis of CYP1A1, CYP1A2, and CYP1B1.
  • Sequence alignment to identify amino acid differences.
  • Root Mean Square Deviation (RMSD) and B-factor analysis to assess protein dynamics.

Main Results:

  • Identified distinct amino acid residues among CYP1 family isoforms, potentially explaining differential substrate specificity.
  • Characterized six putative substrate recognition sequences and their structural locations.
  • RMSD and B-factor analyses highlighted residues with significant deviations, correlating with protein dynamics.

Conclusions:

  • Structural variations in CYP1 family isoforms contribute to their substrate specificity.
  • Insights into protein dynamics and structure-function relationships are crucial for drug development.
  • This study provides a foundation for designing targeted anticancer agents metabolized by CYP1A1.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
303
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
4.8K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.4K